Competitor Analysis: PPAR Agonists
Product description
The present Competitive Intelligence Report about PPAR Agonists provides a competitor evaluation in the field of peroxisome proliferator-activated receptor targeting small molecule agonists for treatment of type 2 diabetes and/or dyslipidemia as of August 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Despite the tremendous attrition rate of PPAR agonist R&D over the last 20 years, the ones in the market are commercially quite successful and spur development of improved successors. The current reassessment of benefit/risk ratio of the classical PPAR gamma agonist rosiglitazone by the FDA and the EMA highlights the need for safer PPAR agonists. One promising approach to achieve effective, but still well tolerated PPAR gamma agonists are selective PPAR gamma modulating agents. Other approaches try to combine PPAR alpha, gamma and delta agonism in one molecule and to find the right balance.
The report includes a compilation of marketed products and current active projects in research and development of PPAR Agonists in type 2 diabetes and/or dyslipidemia. In addition, the report lists company-specific R&D pipelines of PPAR agonists. Competitor projects are listed in a tabular format providing information on:
Index
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low
The present Competitive Intelligence Report about PPAR Agonists provides a competitor evaluation in the field of peroxisome proliferator-activated receptor targeting small molecule agonists for treatment of type 2 diabetes and/or dyslipidemia as of August 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Despite the tremendous attrition rate of PPAR agonist R&D over the last 20 years, the ones in the market are commercially quite successful and spur development of improved successors. The current reassessment of benefit/risk ratio of the classical PPAR gamma agonist rosiglitazone by the FDA and the EMA highlights the need for safer PPAR agonists. One promising approach to achieve effective, but still well tolerated PPAR gamma agonists are selective PPAR gamma modulating agents. Other approaches try to combine PPAR alpha, gamma and delta agonism in one molecule and to find the right balance.
The report includes a compilation of marketed products and current active projects in research and development of PPAR Agonists in type 2 diabetes and/or dyslipidemia. In addition, the report lists company-specific R&D pipelines of PPAR agonists. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index
- PPAR alpha Agonists
- PPAR gamma Agonists / Insulin Sensitizer
- PPAR alpha and gamma Agonists
- PPAR delta Agonists
- PPAR gamma and delta Agonists
- PPAR pan Agonists (alpha, gamma and delta)
- Corporate PPAR Agonist Product Portfolios and R&D Pipelines
- About La Merie
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low
